Study of Patients With Strongyloides Stercoralis Infection
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party)
National Institutes of Health Clinical Center (CC)
First received: November 3, 1999
Last updated: August 24, 2009
Last Verified: May 2009
History of Changes
This study will explore faster and easier ways to detect infection with the intestinal
parasite Strongyloides stercoralis and learn more about the conditions under which it causes
serious disease. Ordinarily, the Strongyloides helminth (type of intestinal worm) causes only
few, if any, symptoms, but in people with weakened immunity it may be very serious, and even
People between 5 and 80 years of age with known or suspected S. stercoralis infection, or infection with another helminth, such as filariasis, that might cause a cross-reaction with S. stercoralis may be eligible for this study.
Participants found to be infected with S. stercoralis will be treated with ivermectin, thiabendazole, or albendazole. In addition, they will undergo the following tests and procedures:
- Blood tests and stool samples: Samples will be collected before and after treatment to check general health status and immune function, and to look for parasites in stool. Up to 50 milliliters (10 teaspoons) of blood will be drawn in adults and up to 25 ml (5 teaspoons) in children.
- Skin tests: A test similar to those used for tuberculosis and allergies will be
|Official Title:||Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis|
Further study details as provided by National Institutes of Health Clinical Center (CC):
|Study Start Date:||August 1989|
|Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
This study is directed to patients with known or suspected Strongyloides stercoralis infection because it is a relatively common parasitic infection, even in the United States. It is difficult to diagnose, and efficacy of treatment is difficult to evaluate. Some infected individuals can develop serious even fatal, disease under certain conditions of immunosuppression. Because newer diagnostic methods are needed to diagnose this infection, we have developed new diagnostics that will be evaluated in comparison to more standard diagnostic tests. Serum and cells will also be collected from patients on this protocol to understand the cellular and humoral response to the parasite and its antigens. All subjects proven to have Strongyloides stercoralis infection will be treated with standard therapy and followed to assess both the efficacy of treatment and the changes in humoral and cellular immune responses induced by treatment.Eligibility
|Ages Eligible for Study:||8 Years to 80 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- INCLUSION CRITERIA:
Access to primary medical care provider outside of the NIH
Ability to give written informed consent (for adults) and parental consent (for those under 18)
Presence of known or suspected infection with Stronglyloides stercoralis, such as significant peripheral blood eosinophilia (greater than 1000 eosinophils/mm(3)) for which no other cause is apparent.
Willingness to participate and provide blood for in vitro assays and serum storage.
Less than 5 years of age
Pregnancy is not a criterion for exclusion.
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001245
Locations Show More
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
Sponsors and CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)
|Responsible Party:||National Institute of Allergy and Infectious Diseases (NIAID)|
|ClinicalTrials.gov Identifier:||NCT00001245 History of Changes|
|Other Study ID Numbers:||890174|
|Study First Received:||November 3, 1999|
|Last Updated:||August 24, 2009|
Keywords provided by National Institutes of Health Clinical Center (CC):Strongyloidiasis
Immediate Hypersensitivity Skin Test
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on October 17, 2017
This information is provided by ClinicalTrials.gov.